
Virginia Kaklamani
Contributor at OncLive
Articles
-
3 weeks ago |
oncnursingnews.com | Virginia Kaklamani |Megan Kruse
June 2, 2025By Panelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant.
-
3 weeks ago |
oncnursingnews.com | Virginia Kaklamani |Megan Kruse
June 2, 2025By Panelists discuss how real-world studies have shown improved outcomes with elacestrant compared with the original EMERALD trial data, demonstrating that proper patient selection leads to better treatment responses.
-
3 weeks ago |
oncnursingnews.com | Virginia Kaklamani |Megan Kruse
June 2, 2025By Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its FDA approval for this specific population.
-
3 weeks ago |
oncnursingnews.com | Virginia Kaklamani |Megan Kruse
June 2, 2025By Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 and PIK3CA mutations.
-
3 weeks ago |
oncnursingnews.com | Virginia Kaklamani |Megan Kruse
Video content above is prompted by the following: Clinical Brief: Second-Line Treatment Decision Framework Main Discussion Topics: Integration of patient factors in treatment selection Balance between efficacy and quality-of-life considerations Practical considerations: insurance, copays, administration route Sequential versus concurrent treatment strategies Role of shared decision-making in complex treatment landscape Key Points for Physicians: Treatment selection requires balance of...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →